Key result
CAMP-PDE inhibitors produced complete relaxation of U46619-induced contractions in human internal mammary artery rings, and amrinone attenuated norepinephrine-induced constriction to 38%.
Why the study?
Do phosphodiesterase inhibitors reverse constriction in human internal mammary artery rings in vitro?
Do phosphodiesterase inhibitors reverse constriction in human internal mammary artery rings in vitro?
cAMP-PDE inhibitors can reverse internal mammary artery spasm in vitro, suggesting potential therapeutic utility after myocardial revascularization.
Answers are grounded in this paper and cite their sources.
Should not yet change perioperative IMA management; leaves open need for in vivo human trials.
The internal mammary artery (IMA) is the preferred conduit for myocardial revascularization, but it changes diameter in response to injury or thromboxane release to decrease myocardial blood supply.Papaverine, a phosphodiesterase (PDE) inhibitor, is injected in the IMA bed during surgery to prevent spasm. We evaluated the ability of papaverine and cyclic adenosine monophosphate PDE Type III (cAMP-PDE) inhibitors (amrinone, enoximone, and milrinone) in vitro to reverse the constriction of human IMA rings, induced by a thromboxane A2 analog, U46619, and evaluated amrinone's ability to modify the constricting effect of norepinephrine (NE). All cAMP-PDE inhibitors produced complete relaxation of U46619-induced contractions. The concentrations necessary to produce 50% relaxation (EC50) were within therapeutic ranges. The vasodilatory potency of amrinone was greater after NE than after U46619 (EC50, 1.9 +/- 0.5 vs 4.3 +/- 2.2 times 10-5 M; mean +/- SD; P < 0.05). Response to constriction after a submaximal dose of NE was attenuated to 38% (P < 0.001) from that observed in the control rings by a pretreatment with amrinone. These results suggest that cAMP-PDE inhibitors have the potential utility to reverse IMA spasm, and represent a potential therapeutic modality for IMA spasm after myocardial revascularization. (Anesth Analg 1996;82:954-7)
No takes yet. Share an insight, caveat, or question.
Salmenperä et al. (1996) studied Internal mammary artery spasm (in vitro model). cAMP-PDE inhibitors (amrinone, enoximone, milrinone) vs. Control rings was evaluated on Reversal of constriction of human IMA rings induced by U46619 or norepinephrine (p=<0.001). CAMP-PDE inhibitors produced complete relaxation of U46619-induced contractions in human internal mammary artery rings, and amrinone attenuated norepinephrine-induced constriction to 38%.
Synapse has enriched 10 related papers. Consider them for comparative context: